Soleno Therapeutics stock gains as competitor exits PWS treatment race
PositiveFinancial Markets

Soleno Therapeutics has seen a significant boost in its stock value following the news that a major competitor has exited the race for treatment of Prader-Willi Syndrome (PWS). This development is crucial as it not only strengthens Soleno's position in the market but also highlights the potential for their treatment to become a leading option for patients. Investors are optimistic about the future, as the reduced competition could lead to increased market share and revenue for Soleno.
— Curated by the World Pulse Now AI Editorial System